L&G Healthcare Breakthrough UCITS ETF

Issuer: L&G ETFs

Asset Class: Equity

TER: 49bps

Trading Currency: GBX

Pays Income: False

Listing Date: 02 Jul 2019

Ticker: DOCG

ISIN: IE00BK5BC677

The global healthcare industry is undergoing a significant transformation driven by technological advancements, demographic shifts like aging populations, and an increasing focus on personalized medicine. This fund provides exposure to this dynamic sector, targeting companies at the forefront of healthcare innovation. It invests in firms that are developing groundbreaking treatments, revolutionary medical devices, and advanced digital health solutions, moving beyond traditional pharmaceutical and biotech companies to capture the broader evolution of the sector.

The portfolio is actively managed, allowing the fund managers to select companies they believe have high growth potential across various sub-sectors. This includes areas such as genomics, robotics-assisted surgery, telemedicine, and biopharmaceuticals. By investing in a diversified basket of these innovative companies, investors can gain access to the potential upside from breakthroughs in medical science and technology that aim to improve patient outcomes and create efficiencies within the healthcare system.

This investment offers a way to participate in a long-term structural growth story. The demand for better, more efficient healthcare is universal and persistent. This fund is designed for those looking to capitalize on the convergence of healthcare and technology, positioning their portfolio to benefit from the next wave of medical innovation. As an accumulating share class, any dividends are reinvested back into the fund to help compound growth potential.